Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Prospective, open-label, uncontrolled and multicenter phase I-II study in SCLC patients with
ECOG PS 0-1 who have failed one prior platinum-containing line but no more than one
chemotherapy-containing line. The study will be divided into two parts: a dose-ranging phase
I with escalating doses of PM01183 in combination with a fixed dose of atezolizumab, followed
by a single-arm phase II part with expansion at the RD determined during the phase I.